Literature DB >> 8549726

Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression.

M Giacomo1, E G Franco, C Claudio, C Carlo, D A Anna, D Anna, F Franco.   

Abstract

The prevalence and the risk factors of the human T-cell leukemia virus type I/II (HTLV-I/II) infection were evaluated among 552 individuals at high risk for HIV-1. HTLV infections showed a low (1.6%) prevalence, were restricted to intravenous drug addicts and were due to HTLV-II alone. Moreover, in order to weigh the influence of HTLV-II on the natural history of HIV-1 infection, the clinical outcome of HIV-1 disease was compared between subjects with and without HTLV-II coinfection. Our findings showed that HTLV-II does not adversely affect the outcome of HIV-1 infection. Infact, a slower disease progression has been recorded in some HTLV-II coinfected subjects.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549726     DOI： 10.1007/bf01719304

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN： 0393-2990            Impact factor:   8.082


  33 in total

1.  HTLV seroreactivity in Italian intravenous drug addicts is primarily due to HTLV-II infection.

Authors:  O E Varnier; F Lillo; S S Alexander; R M Forbis; W Present; A Lazzarin
Journal:  JAMA       Date:  1991-02-06       Impact factor: 56.272

2.  HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation.

Authors:  J A Zack; A J Cann; J P Lugo; I S Chen
Journal:  Science       Date:  1988-05-20       Impact factor: 47.728

3.  HTLV-II associated myelopathy in 43-year-old woman. REDS Investigators.

Authors:  E L Murphy; J W Engstrom; K Miller; R A Sacher; M P Busch; C G Hollingsworth
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

4.  HTLV-II among injecting drug users in Stockholm.

Authors:  A Krook; J Blomberg
Journal:  Scand J Infect Dis       Date:  1994

Review 5.  Immunopathogenesis of HIV infection.

Authors:  Z F Rosenberg; A S Fauci
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

6.  Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia.

Authors:  T P Loughran; T Coyle; M P Sherman; G Starkebaum; G D Ehrlich; F W Ruscetti; B J Poiesz
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

Review 7.  Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group.

Authors: 
Journal:  Ann Intern Med       Date:  1993-03-15       Impact factor: 25.391

8.  Chronic neurodegenerative disease associated with HTLV-II infection.

Authors:  B Hjelle; O Appenzeller; R Mills; S Alexander; N Torrez-Martinez; R Jahnke; G Ross
Journal:  Lancet       Date:  1992-03-14       Impact factor: 79.321

9.  Tropical spastic paraparesis-like illness occurring in a patient dually infected with HIV-1 and HTLV-II.

Authors:  J R Berger; A Svenningsson; S Raffanti; L Resnick
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

10.  HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users.

Authors:  A Visconti; L Visconti; R Bellocco; N Binkin; G Colucci; L Vernocchi; M Amendola; D Ciaci
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-11
View more
  7 in total

1.  Increased all-cause and cancer mortality in HTLV-II infection.

Authors:  Hope H Biswas; Zhanna Kaidarova; George Garratty; Joan W Gibble; Bruce H Newman; James W Smith; Alyssa Ziman; Joy L Fridey; Ronald A Sacher; Edward L Murphy
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone.

Authors:  George A Yendewa; Foday Sahr; Antonio Aguilera; Sulaiman Lakoh; Momodu Sesay; Gibrilla F Deen; Lucia Patiño; Eva Poveda; Robert A Salata
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

3.  Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Authors:  Shari N Gordon; Anna R Weissman; Valentina Cecchinato; Claudio Fenizia; Zhong-Min Ma; Tzong-Hae Lee; Lorenzo Zaffiri; Vibeke Andresen; Robyn Washington Parks; Kathryn S Jones; Jean Michel Heraud; Maria Grazia Ferrari; Hye Kyung Chung; David Venzon; Renaud Mahieux; Edward L Murphy; Steven Jacobson; Christopher J Miller; Francis W Ruscetti; Genoveffa Franchini
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

Review 4.  HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status.

Authors:  Elisabetta Pilotti; Maria V Bianchi; Andrea De Maria; Federica Bozzano; Maria G Romanelli; Umberto Bertazzoni; Claudio Casoli
Journal:  Front Microbiol       Date:  2013-12-23       Impact factor: 5.640

5.  Clinical and Laboratory Outcomes in HIV-1 and HTLV-1/2 Coinfection: A Systematic Review.

Authors:  Iris Montaño-Castellón; Cleyde Sheyla Chachaqui Marconi; Clara Saffe; Carlos Brites
Journal:  Front Public Health       Date:  2022-03-07

6.  Induction of CC-chemokines with antiviral function in macrophages by the human T lymphotropic virus type 2 transactivating protein, Tax2.

Authors:  Glorilee Balistrieri; Christy Barrios; Laura Castillo; Tochi C Umunakwe; Chou-Zen Giam; Huijun Zhi; Mark A Beilke
Journal:  Viral Immunol       Date:  2013-01-03       Impact factor: 2.257

7.  Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study.

Authors:  Jennie R Orland; Baoguang Wang; David J Wright; Catharie C Nass; George Garratty; James W Smith; Bruce Newman; Donna M Smith; Edward L Murphy
Journal:  Retrovirology       Date:  2004-03-24       Impact factor: 4.602
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.